Stock BSLN BASILEA PHARMACEUTICA AG
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Real-time Estimate Cboe Europe
Other stock markets
 06:10:05 2024-05-29 am EDT 		5-day change 1st Jan Change
42.78 CHF -1.55% Intraday chart for Basilea Pharmaceutica AG -0.46% +21.95%
May. 16 Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales MT
May. 16 Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ

Evolution of the average Target Price on Basilea Pharmaceutica AG

Price target over the last 5 years

History of analyst recommendation changes

0cb18786127320b6.jzvhfYu8Y2LwEu9vf0lLRy7b9Dr4w1m70ADG9_1WNMI.yleZG6bMDy-kX7A-Ki0OCFzpuGq5qgDLn1Pzh80Xc7fHboQ--IonDaorug~54340e605b701898f43b0c0f5d5d92e0

Analyst Recommendations on Basilea Pharmaceutica AG

Stronger-than-Expected US Inflation Rate Weighs on Swiss Equities MT
Swiss Equities Rise as Unemployment Rate Falls MT
Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cancer Patients MT
BASILEA PHARMACEUTICA : Edison Investment Research Lowers Price Target on Basilea Pharmaceutica MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
43.45 CHF
Average target price
70.58 CHF
Spread / Average Target
+62.45%
High Price Target
105 CHF
Spread / Highest target
+141.66%
Low Price Target
40.5 CHF
Spread / Lowest Target
-6.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Basilea Pharmaceutica AG

Edward Jones

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BSLN Stock
  4. Consensus Basilea Pharmaceutica AG